<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Sponsor</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Friday, May 25, 2018</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>09.45-10.45</td>
<td>C1-M0</td>
<td>PACE-CME - Boehringer Ingelheim / Lilly</td>
</tr>
<tr>
<td>13.15-14.45</td>
<td>C1-M0</td>
<td>PACE-CME - Resverlogix</td>
</tr>
<tr>
<td>13.15-14.45</td>
<td>C1-M1-2</td>
<td>Fresenius Medical Care</td>
</tr>
<tr>
<td>13.15-14.45</td>
<td>Auditorium 10-11-12</td>
<td>Baxter Healthcare</td>
</tr>
<tr>
<td>13.15-14.45</td>
<td>Auditorium 15</td>
<td>Amgen Europe</td>
</tr>
<tr>
<td>13.15-14.45</td>
<td>Congress Hall A3</td>
<td>Danone Nutricia Research</td>
</tr>
<tr>
<td>13.15-14.45</td>
<td>C1-M3</td>
<td>AstraZeneca Pharmaceuticals LP</td>
</tr>
<tr>
<td>13.15-14.45</td>
<td>C1-M4</td>
<td>Sanofi Genzyme</td>
</tr>
<tr>
<td>13.15-14.45</td>
<td>C1-M5</td>
<td>MSD</td>
</tr>
<tr>
<td>13.15-14.45</td>
<td>C1-M0</td>
<td>Vifor Fresenius Medical Care Renal Pharma</td>
</tr>
<tr>
<td>18.45-19.45</td>
<td>C1-M3</td>
<td>Siemens Healthineers</td>
</tr>
<tr>
<td>18.45-19.45</td>
<td>C1-M0</td>
<td>Zydus Trans-immune (A Division of Cadila Healthcare)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Sponsor</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Saturday, May 26, 2018</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>09.45-10.45</td>
<td>C1-M3</td>
<td>Asahi Kasei Medical Europe</td>
</tr>
<tr>
<td>09.45-10.45</td>
<td>C1-M4</td>
<td>Otsuka Pharmaceutical Europe</td>
</tr>
<tr>
<td>09.45-10.45</td>
<td>C1-M0</td>
<td>Shire International</td>
</tr>
<tr>
<td>13.15-14.45</td>
<td>C1-M3</td>
<td>Terumo BCT</td>
</tr>
<tr>
<td>13.15-14.45</td>
<td>C1-M4</td>
<td>NxStage Medical</td>
</tr>
<tr>
<td>13.15-14.45</td>
<td>C1-M5</td>
<td>Medice Arzneimittel Pütter</td>
</tr>
<tr>
<td>13.15-14.45</td>
<td>C1-M0</td>
<td>Amicus Therapeutics</td>
</tr>
</tbody>
</table>
Diabetic Kidney Disease: Exploring mechanisms and outcomes of SGLT2 inhibition

EBAC ACCREDITED SYMPOSIUM TO BE HELD DURING ERA EDTA 2018, COPENHAGEN, DENMARK

CHAIRMAN
Colin Baigent, MD
University of Oxford, United Kingdom

AGENDA
09:45 – 10:00  SGLT2 inhibition in Kidney Disease: What are the key lessons from the EMPA-REG OUTCOME trial?
Christoph Wanner, MD – University of Würzburg, Germany

10:00 – 10:20 Understanding CKD & SGLT2 inhibition: What are the key mechanisms for benefit?
Per-Henrik Groop, MD – Helsinki University and Helsinki University Hospital, Finland

10:20 – 10:40 Addressing the remaining questions on SGLT2 & CKD: A review of new outcome trials
Colin Baigent, MD – University of Oxford, United Kingdom

10:40 – 10:45 Discussion
All faculty

FRIDAY, MAY 25 2018, 09:45 – 10:45 HRS • MEETING ROOM C1-M0

Supported by an unrestricted educational grant from Boehringer Ingelheim/Lilly.

In compliance with EBAC guidelines, all speakers/chairpersons participating in this programme have disclosed or indicated potential conflicts of interest which might cause a bias in the presentations. The Organising Committee/Course Director is responsible for ensuring that all potential conflicts of interest relevant to the event are declared to the audience prior to the CME activities.
Dear Colleague

I am very pleased to welcome you to this symposium entitled ‘Controversies surrounding RAASi treatment and hyperkalaemia in cardio-renal patients’, sponsored by Vifor Fresenius Medical Care Renal Pharma.

We will start the symposium by introducing a patient case study, which will be used by our internationally renowned faculty to place clinical trial evidence into real-world clinical context. After a presentation on the pathophysiology of recurrent hyperkalaemia by Professor Biff F. Palmer (USA), we will consider the relationship between renin–angiotensin–aldosterone system inhibitor (RAASI) therapies and elevated potassium levels with a particular focus on the renoprotective effects of these treatments. Professor Laurent Juillard (France) will explain how current guidelines recommend discontinuation, dose reduction or withholding initiation of RAASi in patients with, or at risk of, hyperkalaemia, and that these approaches may prevent patients from attaining optimal cardiovascular and renal benefits and outcomes. There is rationale to suggest that new potassium binders may offer a potential solution to this predicament. In the final presentation, Professor Bertram Pitt (USA) will summarize the evidence suggesting how these new potassium binders may enable physicians to better manage and control the risk of hyperkalaemia in patients with chronic kidney disease with comorbidities – such as heart failure or diabetic nephropathy, so that they can initiate, maintain or optimize RAASi therapy. We will conclude with a roundtable discussion, where we will consider how new potassium binders might be used in clinical practice and answer questions from the audience.

This symposium promises to be an informative educational session with an engaging discussion that will be relevant to your clinical practice. I encourage you to submit your questions throughout the symposium via www.pigeonhole.at (Event passcode: RAASi) or by completing the question cards provided and handing them to an organizer.

Professor John Cunningham
Chair

55th ERA-EDTA Congress 2018
Copenhagen, Denmark

Controversies surrounding RAASi treatment and hyperkalaemia in cardio-renal patients

Chair: Professor John Cunningham

Friday 25 May 2018
13:30–14:30
Bella Center Copenhagen
Hall A2

P R O G R A M M E

13:15 Lunchboxes will be provided
13:30 Welcome and introduction
   Professor John Cunningham (UK)
13:35 Pathophysiology of recurrent hyperkalaemia
   Professor Biff F. Palmer (USA)
13:50 RAASI benefits in slowing down kidney function decline
   Professor Laurent Juillard (France)
14:05 New treatment options in hyperkalaemia management
   Professor Bertram Pitt (USA)
14:20 Roundtable discussion and meeting close
   All

www.era-edta2018.org
Expanded haemodialysis: A step closer to natural kidneys

**Industry Symposium**
Friday 25 May 2018
13:30–14:30
Auditorium 10–12
Bella Center Copenhagen

Lunch will be provided at 13:15

**Programme**
- Introductions and welcome
- Middle molecules: State of the art
  - Ziad Massy
- Inflammation, heart disease and large middle molecules: What is the evidence?
  - Peter Stenvinkel
- Expanded haemodialysis: Translating innovation into clinical solutions
  - Claudio Ronco
- Panel discussion and Q&A
- Summary and close

**Scientific Chair**
Claudio Ronco, Italy

**Faculty**
Ziad Massy, France
Peter Stenvinkel, Sweden
Claudio Ronco, Italy
High-volume HDF
Time to shift the renal replacement paradigm and improve patient outcomes

Fresenius Medical Care Scientific Symposium

What is the evidence for improved outcomes with high-volume HDF
Peter Blankestijn (The Netherlands)

How to successfully prescribe, implement and achieve high-volume HDF
Francisco Maduell (Spain)

What did we learn about high-volume HDF in high risk patient populations
Martin Kuhlmann (Germany)

Chairmen
Andrew Davenport (United Kingdom)
Peter Blankestijn (The Netherlands)

May 25th, 2018, 13:15 – 14:45
at the 55th ERA-EDTA Congress
Copenhagen
Venue: Meeting room C1-M1-2
Recent advances in pathophysiology and management of CKD-MBD

Welcome and Introduction
Marianne Rix
Copenhagen | Denmark

New insights into the role of FGF-23 in CKD-MBD and beyond
Marc G. Vervloet
Amsterdam | Netherlands

Management of secondary hyperparathyroidism with injectable etelcalcetide
Markus Ketteler
Coburg | Germany

Programme:
13:30  Lunch
13:45  Scientific programme starts
14:45  Scientific programme ends

55th ERA-EDTA Congress, Copenhagen | Denmark
Friday, 25th May, 13:30 - 14:45
Bella Center, Copenhagen, Auditorium 15

Chaired by Marianne Rix, Copenhagen | Denmark
Official Lunch Symposium of the 55th ERA-EDTA Congress

AGENDA

Chair: Louise Moist, M.D., M.Sc., Schulich School of Medicine & Dentistry, University of Western Ontario, London, Canada.

Plasma copeptin as predictor of Cardio-renal disease: population-based prospective cohort studies and a mendelian randomization approach
Sofia Enhörning, M.D., Ph.D., Skåne University Hospital, Lund University, Malmö, Sweden

Prevention of Recurrent Acute Uncomplicated Cystitis by Increasing Daily Water in Premenopausal Women: A prospective Randomized Controlled Study
Mariacristina Vecchio, PharmD., Danone Research, Palaiseau, France

Increase water intake in first stage CKD patients: results of a Randomized Controlled Trial

Lunchboxes will be available

May 25th • 13h15-14h45
Congress Hall A3 • Copenhagen, DENMARK
SGLT2 inhibitors of today for the renal patient of tomorrow: Does the future look bright?

Looking into the future

Through a series of engaging conversations, world-renowned renal disease experts Professor David Wheeler (UK), Professor Mark Cooper (Australia) and Professor Peter Rossing (Denmark) will reveal what the future holds for the renal patient of tomorrow.

Friday, 25th May 2018; 13:30–14:45; Meeting Room C1-M3

Supported by an unrestricted educational grant from AstraZeneca Pharmaceuticals LP

In compliance with EBAC guidelines, all speakers/Chairpersons participating in this programme have disclosed or indicated potential conflicts of interest which might cause a bias in the presentations. The Organising Committee/ Course Director is responsible for ensuring that all potential conflicts of interest relevant to the event are declared to the audience prior to the CME activities.

This educational event aims to:

1. Highlight current epidemiological trends and treatments, and the unmet needs in patients with chronic kidney disease (CKD)
2. Help delegates understand the potential roles and mechanisms of SGLT2 inhibitors in CKD, and the rationale and design of ongoing renal outcomes trials with SGLT2 inhibitors
3. Foster discussion between the audience and the speakers on what the future will be for patients with CKD

Agenda

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Faculty</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:30–13:45</td>
<td>Lunch</td>
<td></td>
</tr>
<tr>
<td>13:45–13:50</td>
<td>Let’s meet the renal patient of today – a changing profile for the future?</td>
<td>Prof. Mark Cooper (Australia)</td>
</tr>
<tr>
<td>13:50–14:05</td>
<td>Residual risk for the renal patient – the unmet need for early diagnosis and management</td>
<td>All (Discussion)</td>
</tr>
<tr>
<td>14:05–14:15</td>
<td>SGLT2 inhibitors for our renal patients of today and tomorrow – does the future look bright?</td>
<td>Prof. David Wheeler (UK)</td>
</tr>
<tr>
<td>14:15–14:25</td>
<td>The safety profile of SGLT2 inhibitors – can we improve the clinical experience of patients with CKD?</td>
<td>All (Discussion)</td>
</tr>
<tr>
<td>14:25–14:35</td>
<td>Bringing the pieces together – understanding the mechanisms of SGLT2 inhibitors</td>
<td>Prof. Peter Rossing (Denmark)</td>
</tr>
<tr>
<td>14:35–14:45</td>
<td>Making the most of SGLT2 inhibition – can we better our patients’ future?</td>
<td>All (Discussion)</td>
</tr>
</tbody>
</table>
SATELLITE SYMPOSIUM

FABRY DISEASE: FROM INNOVATIVE DIAGNOSIS TO SENSIBLE THERAPEUTIC OBJECTIVES

Chair: Prof. Christoph Wanner

Hidden Fabry Disease in ESRD Patients with unknown diagnosis and suggestive signs of Fabry
Prof. Giuseppe Castellano

Therapeutic goals in Fabry disease: European expert consensus recommendations based on current clinical evidence
Prof. Alberto Ortiz

Fabry disease under ERT: new insights in efficacy of different dosages
Dr Malte Lenders

LUNCH TO BE PROVIDED

PLEASE VISIT OUR BOOTH 2.325
HEPATITIS C: TO TREAT OR NOT TO TREAT?

FRIDAY, 25 MAY 2018
13:30 – 14:30

AGENDA

13:30 – 13:35 Welcome and Opening Remarks
Annette Bruchfeld

13:35 – 13:50 To Treat or Not to Treat: Benefit to the Patient
Paul Martin

13:50 – 14:05 To Treat or Not to Treat: Benefit to the Nephrologist
Michel Jadoul

14:05 – 14:20 What’s Working: Models of Care
Kevin Chan

14:20 – 14:30 Q&A and Closing Remarks
Faculty

CHAIR
Annette Bruchfeld
Associate Professor
Karolinska Institute
Department of Renal Medicine
Karolinska University Hospital
Huddinge
Stockholm, Sweden

FACULTY
Kevin Chan
Massachusetts General Hospital
Fresenius Kidney Care
Boston, Massachusetts, USA

Michel Jadoul
Head, Department of Nephrology
Cliniques Universitaires Saint-Luc
Service de Nephrologie
Brussels, Belgium

Paul Martin
Professor of Medicine
Chief, Divisions of Gastroenterology and Hepatology
University of Miami
Miller School of Medicine
Miami, Florida, USA

LEADERSHIP • COMMITMENT • INNOVATION
More Than 30 Years of Innovation and Commitment to Patients With Chronic Hepatitis C Virus (HCV) Infection

LEADERSHIP • COMMITMENT • INNOVATION
More Than 30 Years of Innovation and Commitment to Patients With Chronic Hepatitis C Virus (HCV) Infection

Copyright © 2018 Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA. All rights reserved. INF-1253686-0000 04/18
Epigenetics in CKD & CVD: A potential breakthrough therapy?

EBAC ACCREDITED SYMPOSIUM TO BE HELD DURING ERA EDTA 2018, COPENHAGEN, DENMARK

CO-CHAIRMEN
Vincent M Brandenburg, MD
Nephrologist, Aachen, Germany
Kamyar Kalantar-Zadeh, MD
UC Irvine School of Medicine, Irvine, CA, USA

AGENDA
13:30 – 13:35 Introduction
Vincent M Brandenburg, MD – Nephrologist, Aachen, Germany

13:35 – 13:50 Cardiovascular disease in diabetes and CKD & residual risk: The promise of epigenetics
Erik Stroes, MD – Academic Medical Centre, Amsterdam, The Netherlands

13:50 – 14:05 Epigenetics in CKD: Rationale for BET inhibition, an emerging therapeutic mechanism in renal disease and CVD
Louise Nordfors, PhD – Karolinska Institute, Stockholm, Sweden

14:05 – 14:25 A clinical view on BET inhibition in CKD & CVD: Understanding recent data and future perspectives
Kamyar Kalantar-Zadeh, MD – UC Irvine School of Medicine, Irvine, CA, USA

14:25 – 14:30 Discussion & summary
All faculty

FRIDAY, MAY 25 2018, 13:15 – 14:45 HRS • MEETING ROOM C1-MO

Supported by an unrestricted educational grant from Resverlogix.

In compliance with EBAC guidelines, all speakers/teachers/persons participating in this programme have disclosed or indicated potential conflicts of interest which might cause a bias in the presentations. The Organising Committee/Course Director is responsible for ensuring that all potential conflicts of interest relevant to the event are disclosed to the audience prior to the CME activities.
Biomarkers: Covering the Continuum of Chronic Kidney Disease

Siemens Healthineers supports clinicians with fast, accurate test results to detect and monitor the progression and comorbidities of kidney disease. Our innovative diagnostic analyzers and comprehensive portfolio of blood biomarkers provide physicians with routine clinical solutions to effectively and efficiently manage the clinical pathway of kidney disease throughout the continuum of care.

- Neutrophil Gelatinase-associated Lipocalin (NGAL) enables rapid detection of AKI in just 4 hours—more than 6 times faster than creatinine.¹
- Beta-trace Protein (BTP) provides quick, accurate estimation of residual renal function (RRF) without cumbersome and time-consuming 48-hour urine collection.²
- Cystatin C (CysC) allows superior estimation of GFR compared to creatinine-based equations and prediction of end-stage renal disease.³

Visit booth #4.243 and learn how Siemens Healthineers comprehensive portfolio of biomarkers can help improve patient outcomes.

Learn more about AKI and NGAL at our symposium

Friday, 25 May
18:45–19:45
Room C1-M3

³ Grubb A. EJIFCC. 2017 Dec 19;28:268-76.
EXPERT FORUM - KIDNEY TRANSPLANTATION

25th May 2018, Copenhagen
(Bella Center, C1-M0 Meeting room)

Faculty

Prof (Dr) R K Sharma
Former Director & Head - Department of Nephrology and Transplant, SGPGIMS, Lucknow, India

Dr Ashwani Gupta
Sr Consultant & Vice Chairman, Department of Nephrology, Sir Gangaram Hospital and Research Centre, New Delhi, India

Prof (Dr) Sishir Gang
Chairman - Department of Nephrology and Transplant, Mullibhai Patel Urological Hospital, Nadiad, India

Agenda

06.45 PM - 06.50 PM Welcome and Introduction
06.50 PM - 07.10 PM Induction agents in kidney transplant
  Prof (Dr) R K Sharma
07.10 PM - 07.15 PM Q & A session
07.15 PM - 07.35 PM ATLG usage in India - a single centre experience.
  Sir Gangaram Hospital and Research Centre, New Delhi
  Dr Ashwani Gupta
07.35 PM - 07.40 PM Q & A session
07.40 PM - 08.00 PM Approach to ABOi kidney transplant - How we do - Mullibhai Patel Urological Hospital experience
  Prof (Dr) Sishir Gang
08.00 PM - 08.05 PM Q & A session

Chairpersons

Dr D S Ranj, Dr Sankaran Sundar, Dr Anil Kumar Bhatia, Dr Sanjeev Gulati, Dr Abhay Sadre

Zydus Tower Satellite Road, Ahmedabad 380 015, India.
Phone: +91-79-266 88 100 (20 Lines) Fax: +91-79-266 88 453 www.zyodusadila.com
APHERESIS
New intervention strategies

26th May 2018 - 9:45 - 10:45
Room C1-M3, Bella Center ground floor – Hall C

CHAIRMAN
Prof. Antonio Santoro
Bologna, Italy

9:45
Desensitization in ABO incompatible kidney transplant candidates in order to achieve good long-term outcome
Prof. Lionel Rostaing
Grenoble, France

10:00
Rheopheresis in peripheral artery disease: a therapeutic opportunity
Dr. Alfonso Ramunni
Bari, Italy

10:15
Lipid Apheresis and PCSK9-Antibodies: Complementary or Competitive?
Prof. Christoph Wanner
Würzburg, Germany
UP TO SPEED
with Rapid Disease Progression in ADPKD

Saturday 26th May 2018
09:45-10:45
Room C1-M4, Bella Center, Copenhagen

Please join our expert Faculty who will share their real-world clinical experience of:
- The ERA-EDTA guidelines on ADPKD and their practical application
- Identification and management of rapid progression in patients with ADPKD
- Managing challenging cases - an interactive session of clinical scenarios

<table>
<thead>
<tr>
<th>9:45</th>
<th>Welcome and introduction</th>
<th>Professor Thomas Benzing, Germany</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:50</td>
<td>The ERA-EDTA guidelines in clinical practice</td>
<td>Dr Roser Torra, Spain</td>
</tr>
<tr>
<td>10:05</td>
<td>Identifying patients with ADPKD at risk of worsening renal function – the GERMAN Experience</td>
<td>Dr Roman-Ulrich Müller, Germany</td>
</tr>
<tr>
<td>10:20</td>
<td>Clinical scenarios – a practical approach</td>
<td>Professor Yannick Le Meur, France</td>
</tr>
<tr>
<td>10:35</td>
<td>Questions, summary and close</td>
<td>Panel Discussion led by Professor Thomas Benzing, Germany</td>
</tr>
</tbody>
</table>
You are invited to join us at a Shire-organised symposium:

Long-term evidence in CKD
Common and uncommon conditions

Saturday 26 May 2018, 09.45-10.45
Room C1-M0, Bella Center

Welcome and introduction
Chair: Mario Cozzolino – Milan, Italy

Experience and long-term safety data of phosphate binders
Alastair Hutchison – Manchester, United Kingdom

Uncommon: Fabry disease and its treatment
Olivier Devuyyst – Zurich, Switzerland

How do we follow up our Fabry patients?
Trond Jenssen – Oslo, Norway
55th ERA-EDTA Congress 2018, Copenhagen, Denmark

The evolving face of CKD-MBD: can an increased understanding lead to improvements in treatment?

**Programme**

13.15  Welcome  
*Professor Tilman Drüke (France)*

13.20  Understanding the complexity of CKD-MBD  
*Professor Pieter Evenepoel (Belgium)*

13.35  Using our understanding of the evolution of SHPT to choose the right target at the right time  
*Professor David Goldsmith (UK)*

13.50  Balancing theoretical targets with practical considerations for phosphate management  
*Professor Mario Cozzolino (Italy)*

14.05  Panel discussion and closing remarks  
*Professor Tilman Drüke (France)*

Lunch will be provided during this symposium

Date of preparation: April 2018  
CHZH/VEL/18/0023d  
© 2018 Vifor Fresenius Medical Care Renal Pharma Ltd. All rights reserved
Novel applications of remote patient management to improve outcomes in peritoneal dialysis

**Industry Symposium**
Saturday 26 May 2018
13:30–14:30
Auditorium 10–12
Bella Center Copenhagen

**Lunch will be provided at 13:15**

**Scientific Chair**
James Heaf, Denmark

**Faculty**
Valérie Jotterand Drepper, Switzerland
Ramón Paniagua, Mexico
Carlo Crepaldi, Italy

**Programme start time:** 13:30  
**Programme duration:** 60 minutes

**Programme**

- Introductions and welcome
- Identification of catheter dysfunction using automated peritoneal dialysis cycler-embedded remote patient management: Impact on the success of therapy
  Valérie Jotterand Drepper
- Potential role of remote patient management in the early detection of peritonitis
  Ramón Paniagua
- Clinic efficiencies afforded using remote patient management in the peritoneal dialysis unit
  Carlo Crepaldi
- Panel discussion and Q&A
- Summary and close
We cordially invite you to the Alexion-sponsored interactive satellite symposium. The objective of this symposium is to create an interactive debate between experts and participants in the diagnosis and management of TMA around topics of interest to you.

Delegate app
Get involved in the discussion by visiting our delegate app, accessible at tmaconnect.live or by scanning the QR code on this flyer.

Before the symposium
Completing the pre-symposium survey on the delegate app will enable us to enhance the meeting by focussing on your topics of interest. You can also ask our faculty questions – these may be read out during the symposium.

During the symposium
Submit questions to the faculty, and get involved in live voting, all from your smart phone/tablet.

After the symposium
Completing the post-symposium survey on the delegate app will help us improve the way we deliver future symposia.

We look forward to meeting you in Copenhagen and for your participation in our interactive programme.
Malnutrition in dialysis – under-recognized and under-treated problem?
Denis Fouque, Lyon, FR

Single-needle indications and requirements today
Raymond Vanholder, Ghent, BE

Hemodialysis in the elderly – a challenge in the 21st century
Giuliano Brunori, Trento, IT

CHALLENGES
IN DIALYSIS
B. BRAUN LUNCH SYMPOSIUM | EDTA 2018 COPENHAGEN
**Industry Symposium Booklet**

**EBAC ACCREDITED LIVE EDUCATIONAL EVENT HELD DURING THE 55th EUROPEAN RENAL ASSOCIATION - EUROPEAN DIALYSIS AND TRANSPLANT ASSOCIATION CONGRESS**

**COME MEET MR ANDERSEN**

Saturday, 26th May 2018; 13:30–14:45
Hall A3

Innovations in CKD: Can K⁺ binders and HIF stabilisers improve Mr Andersen's life?

You will learn how renowned nephrology experts Professor Biff Palmer (USA), Professor Roberto Pecoits-Filho (Brazil) and Professor Iain Macdougall (UK) would manage Mr Andersen's hyperkalaemia and renal anaemia

Supported by an unrestricted educational grant from AstraZeneca Pharmaceuticals LP

In compliance with EBAC guidelines, all speakers/Chairpersons participating in this programme have disclosed or indicated potential conflicts of interest which might cause a bias in the presentations. The Organising Committee/Course Director is responsible for ensuring that all potential conflicts of interest relevant to the event are declared to the audience prior to the CME activities.

This programme is accredited by the European Board for Accreditation in Cardiology (EBAC) for 1 hour of external CME credit. Each participant should claim only those hours of credit that have actually been spent in the educational activity.

---

**Time** | **Session** | **Faculty**
---|---|---
13:30–13:45 | **Lunch** | All delegates
13:45–13:55 | Chair’s introduction: Let’s meet Mr Andersen | Prof. Biff Palmer (USA)
13:55–14:15 | Is there new hope for managing Mr Andersen’s hyperkalaemia? | Prof. Roberto Pecoits-Filho (Brazil)
14:15–14:35 | Can we treat Mr Andersen’s anaemia without increasing cardiovascular risk? | Prof. Iain Macdougall (UK)
14:35–14:45 | Will these innovations improve Mr Andersen’s and other patients’ lives? | All

---

**Supported by an unrestricted educational grant from AstraZeneca Pharmaceuticals LP**
JOIN US FOR OUR SYMPOSIUM:
CLINICAL CONSIDERATIONS OF PLASMA EXCHANGE

Saturday, 26 May 2018
13:30 to 14:45
Meeting room C1-M3

GET THE LATEST INSIGHT ABOUT THE CLINICAL CONSIDERATIONS
OF THERAPEUTIC PLASMA EXCHANGE (TPE).

- Learn about the difference between centrifugal TPE and membrane TPE
- Understand anticoagulation management during TPE procedures
- Hear about the advantages and disadvantages of the use of different vascular
  access types during TPE procedures

PRESENTERS:

Jan T. Kielstein, MD, FASN, FERA
Director, Medical Clinic V, Hypertension and Nephrology
Tertiary Care and Teaching Hospital
Braunschweig, Germany

Miguel Lozano, MD, PhD
Chief Hemotherapy and Hemostasis Section
Hospital Clinic de Barcelona, Spain
Hematology, Transfusion Medicine
President, European Society for Hemapheresis

Paolo Malvezzi, MD
Head of the Transplantation Unit
Grenoble University Hospital
Grenoble, France

Stop by the Terumo BCT booth in the exhibit hall throughout the Congress.
INVITATION TO THE NXSTAGE SYMPOSIUM
SATURDAY • MAY 26, 2018 • 13:30 - 14:45 • ROOM C1- M4

COMPLEX PATIENTS
MAY BE BETTER TREATED WITH
FREQUENT HEMODIALYSIS*

Moderated by: Dr. Mari Vilpakka, Lahti, Finland

Dr Allan Collins, Minneapolis, USA
Prescribing Frequent HD: Addressing Unmet Needs in Dialysis

Dr Natalie Borman, Portsmouth, UK
Managing Hemodynamic Instability: Improving Blood Pressure, Cardiac Stability, and Intradialytic Tolerability

Dr Maxence Ficheux, Caen, France
Managing Complex Cases: Prescribing Improved Outcomes with Obese and Pregnant Patients

Dr Sunita Nair, Shrewsbury, UK
More Frequent Home HD and Palliative Care: Is it Time for a Paradigm Shift?

The NxStage System One is a prescription device. All forms of hemodialysis, including treatments performed in-center and at home, involve some risks. When vascular access is exposed to more frequent use, infection of the site, and other access related complications may be potential risks. In addition, there are certain risks unique to treatment in the home environment. Patients differ and not everyone will experience the reported benefits of more frequent home hemodialysis. Talk to your doctor to see if more frequent home hemodialysis with NxStage is right for you. Certain risks associated with hemodialysis treatment are increased when performing nocturnal therapy due to the length of treatment time and because therapy is performed while the patient and care partner are sleeping.

*The symposium presenters are paid speakers and/or consultants speaking on behalf of NxStage Medical UK, Ltd.

VISIT THE NXSTAGE BOOTH #2.241
FOR MORE INFORMATION

NxStage Medical, Inc. is a leading medical technology company that develops, manufactures and markets innovative products for the treatment of ESRD and acute kidney failure. The NxStage® System One is a portable hemodialysis system cleared for use in patients’ homes giving them the benefit of treatment flexibility. Unlike conventional hemodialysis systems, the System One requires no special infrastructure to operate. Under the guidance of their physician, patients can use the System One, with their trained care partners, where, how and when it best meets their needs, including while they are sleeping - at home or on vacation and at a medically appropriate treatment frequency.
### Scientific Lunch Symposium

**Chair:** Markus Ketteler (Germany)

<table>
<thead>
<tr>
<th>Session</th>
<th>Speaker</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>Welcome and Introduction</td>
<td>Markus Ketteler</td>
<td>Germany</td>
</tr>
<tr>
<td>New Insights in the Physiological and Pharmacological Modulation of Intestinal Phosphate Absorption</td>
<td>Carsten Wagner</td>
<td>Switzerland</td>
</tr>
<tr>
<td>Results of the NOPHOS Study – Combination of Nicotinamide &amp; Phosphate Binders: A New Approach for the Treatment of Therapy Resistant Hyperphosphataemia in Patients with End Stage Renal Disease</td>
<td>Andrzej Wiecek</td>
<td>Poland</td>
</tr>
<tr>
<td>Closing Remarks and Q&amp;A</td>
<td>Markus Ketteler</td>
<td>Germany</td>
</tr>
</tbody>
</table>

**Targeting Intestinal Phosphate Absorption – A New Therapeutic Approach for Control of Hyperphosphataemia**

- **Saturday, 26th May 2018 / 13:30 – 14:45 /
- Meeting Room C1-M5

**Lunch will be provided**
Please join us for a lunch satellite symposium sponsored by Amicus Therapeutics, Ltd.

Recent advances in the diagnosis, treatment and follow-up of renal involvement in Fabry disease

AGENDA & FACULTY

13.30 Welcome, Introductions

13.35 Overview of migalastat phase three clinical trials with an emphasis on renal data
Daniel G. Bichet, MD (Canada)

13.55 Quantitative unbiased electron microscopic morphometric methods in evaluating kidney pathology in Fabry disease. Results from the migalastat FACETS trial
Behzad Najafian, MD (United States)

14.15 The role of renal biopsies in the diagnosis and follow-up of Fabry disease
Camilla Tøndel, MD, PhD (Norway)

14.35 Discussion Faculty

14.45 Adjourn

FACULTY

Chaired by Ulla Feldt-Rasmussen, MD, DMSc
Professor, Chief of Medical Endocrinology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark

Daniel G. Bichet, MD, MSc
Professor of Medicine, Pharmacology and Physiology, University of Montreal
Nephrologist, Hôpital Sacré-Coeur de Montréal, Montreal, Québec, Canada

Behzad Najafian, MD
Associate Professor of Pathology, Department of Pathology, University of Washington Medical Center
Seattle, WA, USA

Camilla Tøndel, MD, PhD
Pediatric Nephrologist, Department of Pediatrics, Haukeland University Hospital Renal Research Group, Department of Clinical Medicine, University of Bergen Bergen, Norway

Saturday, 26 May, 2018, 13.30-14.45
Room C1-M0, Ground Floor, Bella Center
55th ERA-EDTA Congress, Copenhagen, Denmark

Migalastat is a pharmacological chaperone approved in the European Union in patients with Fabry disease aged 16 years and older with an amenable mutation. Please see respective country SmPC for Important Safety Information.

Amicus Therapeutics is a global biotechnology company at the forefront of therapies for rare and orphan diseases. The Company has a robust pipeline of advanced therapies for a broad range of human genetic diseases.

Seating and lunches are limited. Distribution of lunches and seating will be first come, first served.